Dementia

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD

Lecanemab and what this means for the future treatment of Alzheimer’s disease

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Ensuring the safety of epigenome therapies in the treatment of Alzheimer’s disease

Future direction for anti-amyloid immunotherapies

Next generation tau tracers: [18F]MK-6420 vs [18F]flortaucipir

Ongoing and future efforts in functional genomics in Alzheimer’s disease

Is amyloid load a valid surrogate endpoint for AD clinical trials?

What’s next for clinical trials in Alzheimer’s disease?

Precision medicine in Alzheimer’s treatment: genetics and co-pathologies

Astrocyte biomarkers associated with amyloid-β and tau pathologies

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Performance of plasma p-tau181 as a community-based screening tool for AD clinical trials

Associations between predicted brain age and Alzheimer’s Disease biomarkers

Lipidomics as a tool for dementia research

Can biomarkers help to predict brain age?